<SEC-DOCUMENT>0001129928-17-000005.txt : 20170508
<SEC-HEADER>0001129928-17-000005.hdr.sgml : 20170508
<ACCEPTANCE-DATETIME>20170508150955
ACCESSION NUMBER:		0001129928-17-000005
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170508
DATE AS OF CHANGE:		20170508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		17821924

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>firstquarter20176-k.htm
<DESCRIPTION>2017 FIRST QUARTER REPORT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s061AF18934E855153CB882B9EFCBFB1B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;  </font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Form 6-K</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Foreign Private Issuer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Rule&#160;13a-16 or 15d-16</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the month of&#160;May </font><font style="font-family:inherit;font-size:10pt;">2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number 000-31062</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Translation of registrant&#8217;s name into English)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite&#160;210, 1167 Kensington Crescent NW</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Calgary, Alberta, Canada T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Address of principal executive offices)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form&#160;20-F&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form&#160;40-F&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;">&#32;Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;">&#32;Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s049A731E826256BBB55D82B9EFFC4398"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NUMBER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Inc. March 31, 2017 Interim Financial Statements</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Inc. March 31, 2017 Management Discussion &amp; Analysis</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:4%;"></td><td style="width:3%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 8, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Kirk Look</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991interimfinancialstate.htm
<DESCRIPTION>2017 FIRST QUARTER INTERIM FINANCIAL STATEMENTS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDAB6770AC6F92EB5E7B982B9F43896D9"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interim Consolidated Financial Statements </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">2016</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sFADCAA8897D72FE8C79882B9E82E336D"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:536px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:304px;"></td><td style="width:40px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,102,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36,484</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,406</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">182,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,321,774</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,438,329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">301,534</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">301,534</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,623,308</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758,284</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities And Shareholders&#8217; Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,348,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,068,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,348,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,068,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and contingencies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share capital<br>&#160;&#160;Authorized: unlimited<br>&#160;&#160;Issued:<br>  March 31, 2017 &#8211; 121,258,222<br>  December 31, 2016 &#8211; 121,258,222</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">262,311,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contributed surplus</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26,776,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,643,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">533,312</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(282,347,028</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(278,829,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,274,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,623,308</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758,284</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;See accompanying notes</font></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sDBC677E420DB4BAB951282B9ED6404DC"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:566px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:316px;"></td><td style="width:66px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three month period ending March 31</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5, 11, 12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,268,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,726,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5, 11, 12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,300,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,360,412</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,568,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,086,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">50,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,621</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,517,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,016,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (expense) recovery</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,517,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,016,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other comprehensive income items that may be</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;&#160;reclassified to net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(20,748</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(170,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,538,467</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,186,834</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">121,258,222</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,119,985</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;&#32;See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s480E4339897E5B73B7DA82B9ECDBF0FF"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:772px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:260px;"></td><td style="width:87px;"></td><td style="width:4px;"></td><td style="width:99px;"></td><td style="width:4px;"></td><td style="width:108px;"></td><td style="width:4px;"></td><td style="width:110px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contributed Surplus</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Deficit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,277,966</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,689,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,674,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(170,059</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,016,775</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,186,834</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(375,349</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(375,349</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,640</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,640</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,224,148</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,359,606</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590,919</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(267,706,105</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,468,568</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contributed Surplus</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Deficit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,643,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(278,829,309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,748</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,517,719</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,538,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;(Note 4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,889</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,889</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">262,311,325</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26,776,933</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">533,312</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(282,347,028</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,274,542</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:84px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s869A2EB275D67C3605EA82B9EBC828B9"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:589px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:350px;"></td><td style="width:60px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three month period ending March 31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,517,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,016,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Amortization - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,036</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,942</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5, 11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">133,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Unrealized foreign exchange loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">52,032</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,295</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in non-cash working capital</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(637,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">724,655</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash used in operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,945,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,023,243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redemption (purchase) of short-term investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash provided by (used in) investing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,082,964</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">"At the Market" equity distribution agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,544</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash used in financing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Decrease in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,872,944</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,151,610</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,034,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,016,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of foreign exchange on cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(58,945</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(631,257</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,102,393</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,233,408</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s9A0FBA883F52585AB9C582B9F501B5A2"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDA37627296730541EC3F82B9ED3B71E4"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 1: Incorporation and Nature of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Oncolytics Biotech Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our interim consolidated financial statements for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">May&#160;4, 2017</font><font style="font-family:inherit;font-size:10pt;">.  We are a limited company incorporated and domiciled in Canada.  Our shares are publicly traded and our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics.  Our lead product, REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies. Our clinical development program for REOLYSIN emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC34445488F8FA8099B8082B9F553EC4B"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 2: Basis of Financial Statement Presentation</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and are presented in Canadian dollars, our functional currency.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accounts are prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) issued by the International Accounting Standards Board (&#8220;IASB&#8221;).  The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These interim consolidated financial statements have been prepared in compliance with International Accounting Standard 34 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Financial Reporting.  </font><font style="font-family:inherit;font-size:10pt;">The notes presented in these interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements.  Accordingly, these interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements, for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.  We have consistently applied the same accounting policies for all periods presented in these interim consolidated financial statements  as those used in our audited consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div><a name="s24C1C4A9B231D5C411D582B9F5857E76"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 3: Cash Equivalents and Short Term Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of interest bearing deposits with our bank totaling $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">7,753,698</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10,679,992</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;The current annual interest rate earned on these deposits is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.90%</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.96%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments which consist of guaranteed investment certificates are liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.&#160;&#160;The objectives for holding short-term investments are to invest our excess cash resources in investment vehicles that provide a better rate of return compared to our interest bearing bank account with limited risk to the principal invested.&#160;&#160;We intend to match the maturities of these short-term investments with the cash requirements of the Company&#8217;s activities and treat these as held-to-maturity short-term investments.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:20%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Face</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Original Cost</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Accrued Interest</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Carrying</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Fair</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Effective</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Interest Rate</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is determined by using published market prices provided by our investment advisor.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFC4C48ECFC87D2A608F082B9EA4CADCB"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 4: Share Capital</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:414px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:242px;"></td><td style="width:80px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,151,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,006,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">121,258,222</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">262,311,325</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an "at-the-market" equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of $4.6 million and allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM").  Subject to the terms of our Canadian ATM,  we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. No common shares were sold during the period ending March 31, 2017. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$10,500</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2EF05C5E195B942E125082B9EEBE3F0C"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 5: Share Based Payments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:214px;"></td><td style="width:111px;"></td><td style="width:4px;"></td><td style="width:117px;"></td><td style="width:112px;"></td><td style="width:4px;"></td><td style="width:117px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,674,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,561,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">125,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(17,900</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,611,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,461,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,579,243</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,376,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.74</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:635px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:134px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:100px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.26 - $0.41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,097,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">846,916</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.42 - $0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,172,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,390,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.58- $1.87</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,587,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.76</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.55</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,587,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.55</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.88 - $3.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,504,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,504,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.04</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.96- $6.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.73</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.33</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.33</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,611,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.10</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,579,243</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.22</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-exercisable options vest annually over periods ranging from one to three years or after the completion of certain performance criteria.   </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the period was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:511px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:245px;"></td><td style="width:133px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.92%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">86.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada marketable bond rate in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Share Award Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued restricted share units to non-employee directors through our incentive share award plan. Grants of restricted share units to non-employee directors vest either on the third anniversary date from the grant date or when the director ceases to be a member of the board. The following restricted share units are outstanding at March 31:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:369px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:205px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,322,829</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the period</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">38,340</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,361,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">386,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:60px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:18px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the restricted share units granted was $</font><font style="font-family:inherit;font-size:8pt;">0.69</font><font style="font-family:inherit;font-size:8pt;">&#32;in 2017 (2016 - $</font><font style="font-family:inherit;font-size:8pt;">0.42</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also issued performance share units to certain officers and management of the Company. Grants of performance share units require completion of certain performance criteria and cliff vest after three years or vest over a three year period, depending on the grant. Grants to officers will vest immediately upon a change of control of the Company. If the officer ceases employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:370px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:206px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">840,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the period</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">900,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:60px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:18px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the performance share units granted was $</font><font style="font-family:inherit;font-size:8pt;">0.35</font><font style="font-family:inherit;font-size:8pt;">&#32;in 2017.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reserved </font><font style="font-family:inherit;font-size:10pt;">11,312,394</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for issuance relating to outstanding stock options. Compensation expense related to stock options granted to employees, directors and consultants, restricted share units to independent directors and performance share units to certain officers and management was </font><font style="font-family:inherit;font-size:10pt;">$133,889</font><font style="font-family:inherit;font-size:10pt;">&#32;for the period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$81,640</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1ABF0561BFF3E840004282B9F5FB79ED"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 6: Loss Per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share is calculated using net loss for the period and the weighted average number of common shares outstanding for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">121,258,222</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">118,119,985</font><font style="font-family:inherit;font-size:10pt;">).  The effect of any potential exercise of our stock options and warrants outstanding during the period has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB6E3F7C6C6F3436E709982B9E78C76D0"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 7: Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to payments totaling </font><font style="font-family:inherit;font-size:10pt;">$1,623,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next twelve months.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases.  Annual payments under the terms of this lease are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:62%;"></td><td style="width:37%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,623</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,512</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">461,289</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sA15E179AF0B6F5D8B85282B9F64D467A"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 8: Capital Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;&#160;We include shareholders&#8217; equity, cash and cash equivalents and short-term investments in the definition of capital.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,<br>2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2016<br>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,102,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,274,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board .&#160;&#160;The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities.&#160;&#160;The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;&#160;Management regularly monitors the capital markets attempting to balance access to capital in different jurisdictions, the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On  February 16, 2016, we renewed our short form base shelf prospectus (the &#8220;Base Shelf&#8221;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#8220;Securities&#8221;) in Canada.  Under our Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received from a Prospectus Supplement will be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf expires on March 16, 2018 and allowed us to enter into our Canadian ATM equity distribution agreement (see Note 4).  We use this equity arrangement to assist us in achieving our capital objective. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3BC39A58A0BA3ED5332482B9F67FCD5C"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 9: Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, short-term investments,&#160;&#160;accounts receivable, and accounts payable.&#160;&#160;As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;&#160;We are exposed to credit risk on our cash and cash equivalents and short-term investments in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and short-term investments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties.&#160;&#160;As at December 31, 2016, 100% of our short-term investments were in guaranteed investment certificates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;&#160;We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.&#160;&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&#160;&#160;In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from financing activities.&#160;The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$17,516</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$34</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,247</font><font style="font-family:inherit;font-size:10pt;">&#32;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:420px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:197px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:70px;"></td><td style="width:4px;"></td><td style="width:64px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">U.S. dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,359,799</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,078</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,524</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:3px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,073,915</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,864</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,524</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 8.&#160;&#160;Accounts payable are all due within the current operating period.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF1AE99CF8753E322D3DD82B9F6A1CB8B"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 10: Additional Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:547px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:392px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77,944</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(719,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(13,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(637,646</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">724,655</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:461px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:342px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">50,715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCDFB6C1856BE0636287F82B9E9156927"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 11:  Other Expenses and Adjustments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses, and non-cash share based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and share based compensation associated with operating activities as a component of operating expenses.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:566px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:420px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(45,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">72,781</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,295</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">67,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,036</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,942</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">66,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">49,069</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,488</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s646239FC94B593567AE182B9F6F4C7D6"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 12:  Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Key Management Personnel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole.  We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:448px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:301px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:70px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">582,395</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667,454</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">98,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">680,886</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">749,094</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992-q12017mda.htm
<DESCRIPTION>2017 FIRST QUARTER MD&A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1344CB622FDB6DA4E24982B9F9C0079A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;"><img src="oncylogoa04.jpg" alt="oncylogoa04.jpg" style="height:160px;width:682px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sC3DD613A3F73E33A572E82B9F9E28C2A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;color:#000000;font-weight:bold;text-decoration:none;">May&#160;4, 2017</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This discussion and analysis should be read in conjunction with the unaudited consolidated interim financial statements of </font><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;as at and for the three months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) contained in our annual report for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.  The financial statements have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;).  </font></div><div><a name="s4C8F1BBF5A220B621D0682B9FA14185E"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation. Forward-looking statements, including our belief as to the potential of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize REOLYSIN, uncertainties related to the research, development and manufacturing of REOLYSIN, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within this MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of REOLYSIN and future expense levels being within our current expectations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.  Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate.  Investors are cautioned against placing undue reliance on forward-looking statements.  We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7E8300ABC22D91218CF082B9FA35445E"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">REOLYSIN</font><font style="font-family:inherit;font-size:16pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;Development Update For </font><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company and we have focused our research and development efforts on the development of REOLYSIN, our potential cancer therapeutic.  We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts.  We do not expect to generate significant revenues until, if and when, our cancer product becomes commercially viable.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal each year is to advance REOLYSIN through the various steps and stages of development required for potential pharmaceutical products.  In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">supply, and our intellectual property.</font></div><div><a name="sA0ACEEBF6472E7041A4282B9FA67E68C"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are directing our clinical development program with the objective of developing REOLYSIN as a human cancer therapeutic.  Our clinical development plan has two main objectives. The primary objective is to obtain regulatory approval for REOLYSIN as quickly as possible and is based on the compelling metastatic breast cancer survival data recently presented at the  2017 American Academy of Cancer Research (AACR) Annual Meeting, in Washington, D.C. The second objective is to expand REOLYSIN into commercially valuable new treatment areas that include immuno-therapy and immuno-modulatory (IMiD) agents in collaboration with pharmaceutical partners. Our clinical development program focuses on the three components of REOLYSIN&#8217;s mechanism of action (MOA) and includes the following three pathways:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Path #1 - Direct Tumour Lysis</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, our focus has been on the investigation of chemotherapy combination clinical trials investigating the use of different chemotherapy agents in various cancer indications. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Path #2 - Innate Immune Response</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our second pathway focuses on the potential of REOLYSIN to stimulate a patient's innate immunity and the potential for an infection to cause a cascade of chemokines/cytokines  activating natural killer (NK) cells to attack cancer cells.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Path #3 - Adaptive Immune Response</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our third pathway focuses on the potential for REOLYSIN to cause a specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs, infected tumor cells and/or dendritic cells) to T cells. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">First Quarter 2017 Developments:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Path #1 - Direct Tumour Lysis - Clinical Trial Results</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Metastatic Breast Cancer Clinical Trial Results </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 4, 2017, the Canadian Cancer Trials Group (CCTG, formerly known as the National Cancer Institute of Canada - NCIC) presented overall survival data from an open-label, randomized, Phase 2 study designed by CCTG at the AACR  Annual Meeting in Washington, DC. The 74-patient study, powered to 90 percent, assessed the therapeutic combination of intravenously-administered REOLYSIN&#160;given in combination with paclitaxel versus paclitaxel alone in patients with advanced or metastatic breast cancer.&#160;  The poster reported survival data from the intention-to-treat (ITT) patient population and from a sub-population of patients with wild type APC metastatic breast cancer.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ITT patient population there was an improvement in median OS from 10.4 months on the control arm (n=38) to 17.4 months on the test arm (n=36) (Hazard ratio 0.65, 80% CI 0.46-0.91, p=0.1), meeting the pre-specified significance level for the 90 percent powered study (figure A). Consistent with REOLYSIN acting as an immune therapy agent, there was no meaningful improvement in either progression free survival or response rate.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure A - Intention-to-Treat Overall Survival</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;"><img src="ittgroup.jpg" alt="ittgroup.jpg" style="height:377px;width:536px;"></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The abstract also reported data that demonstrated a statistically significant (p=0.03) OS benefit for patients with wild type APC metastatic breast cancer, when treated with REOLYSIN in combination with paclitaxel.  Of the 74 patients enrolled with metastatic breast cancer, 81 percent (60 patients) presented with wild type APC tumors. The results showed patients with wild type APC metastatic breast cancer that were treated with REOLYSIN&#160;in combination with paclitaxel (n=31) had a median OS of 20.9 months versus 10.4 months (n=29) in patients treated only with paclitaxel (Hazard Ratio 0.53, 80% CI 0.36-0.78, p = 0.03).  See Figure B.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure B. Wild Type APC Overall Survival</font></div><div style="line-height:120%;text-align:justify;"><img src="apc2.jpg" alt="apc2.jpg" style="background-color:#ffff00;font-weight:bold;height:336px;width:533px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The abstract, authored by Bernstein et al, is titled "A randomized (RCT) phase II study of oncolytic reovirus (pelareorep) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)&#8221;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Path #2 - Innate Immune Response</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial activity supporting the innate immunity component of REOLYSIN's MOA, is in collaboration with Myeloma UK, a cancer charity, and Celgene. MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">&#32;was launched in March of 2017: a first of its kind immuno-therapy trial that aims to modulate the immune system to target myeloma. The Phase 1b trial will study REOLYSIN in combination with Celgene's Imnovid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(pomalidomide) or Revlimid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(lenalidomide) as a rescue treatment in relapsing myeloma patients. The dose escalation trial will look at the safety and tolerability of these combinations, and will investigate whether the addition of REOLYSIN extends disease control in this patient group. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial will recruit approximately 44 patients across up to six Myeloma UK Clinical Trial Network centres in the UK. MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">&#32;is part of the Myeloma UK Clinical Trial Network, a portfolio of early-stage trials coordinated by the Clinical Trials Research Unit at the University of Leeds, which aims to test and speed up access to promising new treatments for patients.  Oncolytics and Celgene UK &amp; Ireland are providing their respective products for MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">: Oncolytics is providing REOLYSIN and Celgene UK &amp; Ireland is providing Imnovid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and Revlimid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Path #3 - Adaptive Immune Response</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In support of the adaptive immunity component of the MOA, we are currently running our first study in combination with an emerging class of immuno-oncology agents known as checkpoint inhibitors. REO 024 is an open-label phase 1b trial to determine the safety and dose-limiting toxicity of REOLYSIN in combination with pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) and chemotherapy in patients with histologically confirmed, advanced or metastatic pancreatic adenocarcinoma who have failed, or did not tolerate, first-line treatment. The goal of this study is to establish the safety profile of the REOLYSIN/KEYTRUDA combination and to determine how a checkpoint inhibitor could improve the immune system's ability to recognize cancer cells through the stimulation of the adaptive immune response in patients caused by REOLYSIN. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s23670ED60805BEC761A382B9FA89806C"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Manufacturing and Process Development </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2017, we supplied our clinical trial program with previously filled and labeled product from our existing supply of REOLYSIN. As well, we continued our validation activities designed to demonstrate that our manufacturing process for the commercial production of REOLYSIN is robust and reproducible as part of a process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company&#8217;s submission to regulators, including the FDA, for product approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE15C4C51381845D8ED5282B9FABA8DE9"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">,  we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">420</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">63</font><font style="font-family:inherit;font-size:10pt;">&#32;U.S. and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents as well as issuances in other jurisdictions.  We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028.  Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div><a name="sF9D5BCB42A925AB6965082B9FADC0AF0"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financing Activity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of  2017, we incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$10,500</font><font style="font-family:inherit;font-size:10pt;">&#32;in order to maintain access to our Canadian "at-the-market" equity distribution agreement with Canaccord Genuity Inc. (our "Canadian ATM").  For the period ending March 31, 2017, we did not utilize our Canadian ATM and did not sell any common shares.  Under the terms of our Canadian ATM, we may, from time to time, sell shares of our common stock having an aggregate offering value of up to $4.6 million through Canaccord Genuity Inc.  Sales of  common shares, if any, pursuant to the Canadian ATM, will be made in transactions that are deemed to be "at-the-market distributions", through the facilities of the Toronto Stock Exchange or other "marketplace" (as defined in National Instrument 21-101 Marketplace Operation) in Canada.  We will determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s8C4374B4A56BE6AB134582B9FB0E53C2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Impact</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimated at the beginning of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;that our cash requirements to fund our operations would be approximately $12 million.  Our cash usage for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,945,408</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;from operating activities and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,836</font><font style="font-family:inherit;font-size:10pt;">&#32;for the acquisition of property and equipment.  Our net loss for the period was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,517,719</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s47B2032FADB4245AAC7582B9FB2FE0AC"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Resources </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We exited the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;with cash and cash equivalents totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10,102,393</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;(see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s63FF4B647A0EB69E079F82B9FB610940"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">REOLYSIN Development for the Remainder of 2017 </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Registration Path in Metastatic Breast Cancer</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 12, 2017, we announced our initial registration pathway which was based on CCTG's compelling clinical results in metastatic breast cancer, where the combined treatment demonstrated a statistically significant increase in median OS.  We have consulted with key opinion leaders to develop our registration strategy and we intend to present our breast data and outcome of our discussions with key opinion leaders to regulators as part of an End-of-Phase 2 Meeting expected to occur later in 2017.  Our objective for an End-of-Phase 2 meeting is to obtain scientific advice to support our registration pathway. Specific features of any future clinical studies are expected to include: overall survival as a primary endpoint; other exploratory endpoints to identify potential markers of response; and a trial design to ensure a sufficient number of patients are run to reach a statistically significant outcome while balancing the financial resources required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Additional Clinical Development </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also expect during the remainder of 2017, that we will expand our research collaborations with large pharma in an effort to support further development around the innate and adaptive immunity components of REOLYSIN's MOA.  We expect these potential collaborations to include combinations with immunotherapies and IMiDs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturing and Intellectual Property </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2017 manufacturing program includes continued production of 100-litre cGMP production runs along with the related fill, labeling, packaging and shipping of REOLYSIN to our various clinical sites.  We also plan to continue progressing through our process validation master plan and related conformity testing in 2017.  Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently estimate the cash requirements to fund our operations for 2017 will be approximately $12 million, but will depend on our ultimate clinical program.  (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s24AB8CE25B6D63F0A44F82B9E97D93F1"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the three month period ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,517,719</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4,016,775</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the three month period  ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.      </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">686,173</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557,224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">453,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">533,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenditures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">251,590</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396,364</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">87,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">694,135</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743,983</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">67,833</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,603</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,268,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,726,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:376px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">686,173</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557,224</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trial expenses for the first quarter of 2017 were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$686,173</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$557,224</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the first quarter of 2016. In the first quarter of 2017, our clinical trial program focused mainly on the preparation and development of a breast cancer registration study (Path #1 of our Clinical Development Plan). These activities included costs to complete our supporting regulatory documents, regulatory filing fees and key opinion leader activities.  During the first quarters of 2017 and 2016, our clinical activities included patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our clinical trial expenses to increase in 2017 compared to 2016. In 2017, we expect to finalize our registration path and complete the regulatory filings necessary to support and commence enrollment in a registration study as part of Path #1 of our Clinical Development Plan. As well, we expect to expand Path #2 and Path #3 of our Clinical Development Plan to include both checkpoint inhibitors and IMiDs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.3203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:71%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">304,501</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">355,035</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">149,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178,484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">453,564</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">533,519</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for the first quarter of 2017 were </font><font style="font-family:inherit;font-size:10pt;">$453,564</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$533,519</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of 2016. During the first quarters of 2017 and 2016, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for the first quarter of 2017 were </font><font style="font-family:inherit;font-size:10pt;">$149,063</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$178,484</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of 2016.  In the first quarter of 2017, our process development activities focused on stability studies. In the first quarter of 2016, our process development activities focused on our validation master plan, which included optimization, validation and stability studies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our M&amp;P expenses for 2017 to increase compared to 2016. In 2017, we expect to fill, label and store sufficient product in preparation for a registration study.  We also expect to continue to perform conformity testing related to our process validation master plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:74%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">251,590</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396,364</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the first quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$251,590</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$396,364</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.  The change in intellectual property expenditures reflects the timing of filing costs associated with our expanded patent base.  At the end of the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">420</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">63</font><font style="font-family:inherit;font-size:10pt;">&#32;U.S. and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions.  We still expect that our intellectual property expenses will remain consistent in 2017 compared to 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:74.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:76%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">87,379</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,119</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$87,379</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$54,119</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.  Our research collaborations during the first quarters of 2017 and 2016 included biomarker studies along with studies investigating the interaction of the immune system and REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect that our research collaborations in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;will remain consistent with </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.  We expect to complete our ongoing collaborative program carried over from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and will continue to be selective in the types of new collaborations we enter into in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">665,818</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">699,089</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">28,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">694,135</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743,983</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Other Research and Development expenses for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$694,135</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$743,983</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.  The change in our R&amp;D salaries and benefits was mainly due to the change in chief executive officers which was partially offset by the addition of our new chief medical officer in November 2016. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect that our Other R&amp;D expenses in 2017 will remain consistent compared to 2016. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:527px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:377px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:63px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">67,833</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,603</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payment expenses for the first quarter of 2017 were </font><font style="font-family:inherit;font-size:10pt;">$67,833</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$59,603</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of 2016. We incurred share based payment expenses associated with performance share awards granted to officers and stock options granted to officers and employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">694,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">827,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">515,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">464,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,036</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,942</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">66,056</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,037</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,300,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,360,412</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings. During the first quarter of 2017, our public company related expenses were </font><font style="font-family:inherit;font-size:10pt;">$694,375</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$827,507</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of 2016. The decline in these costs has been a direct result from a change in our philosophy regarding investor relations (IR) activities. During the first quarter of 2017, we were able to eliminate certain IR services and brought elements of our IR program in house in an effort to maximize the impact of our IR activities while maintaining control over costs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), office rent and other office related costs.  During the first quarter of 2017, we incurred office expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$515,833</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$464,926</font><font style="font-family:inherit;font-size:10pt;">&#32;during the first quarter of 2016. The change was primarily due to a change in salary levels and increase in headcount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payment expenses for the first quarter of 2017 were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$66,056</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$22,037</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first quarter of 2016.  In the first quarters of 2017 and 2016, we incurred share based payment expenses associated with restricted share awards granted to independent board members and stock options granted to officers and employees. We also incurred share based payment expenses associated with performance share awards granted to certain officers and management in the first quarter of 2017.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our operating expenses in 2017 to decrease compared to 2016.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we are committed to payments totaling approximately </font><font style="font-family:inherit;font-size:10pt;">$1,623,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our clinical trial , manufacturing and collaboration programs which are expected to occur over the next twelve months. We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases totaling $</font><font style="font-family:inherit;font-size:10pt;">461,289</font><font style="font-family:inherit;font-size:10pt;">&#32;for 2017 to 2021. All of these committed payments are considered to be part of our normal course of business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB84681E956C4A1F03C9682B9FBB4BFBE"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Quarterly Results</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:614px;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:189px;"></td><td style="width:9px;"></td><td style="width:59px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:38px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:38px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:38px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="9" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,518</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,190</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1), (3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Included in total cash are cash and cash equivalents plus short-term investments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Included in net loss and loss per common share between March 2017 and April 2015 are quarterly share based payment expenses of  </font><font style="font-family:inherit;font-size:8pt;">$133,889</font><font style="font-family:inherit;font-size:8pt;">, $106,443, $98,369, $119,626, $81,640, $248,101, $10,791, and $55,675, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We issued nil common shares from our Canadian ATM for cash proceeds of nil</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:8pt;">and incurred share issue costs of </font><font style="font-family:inherit;font-size:8pt;">$10,500</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:8pt;">in </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;">&#32;(2016 - 3,106,600 common shares for net cash proceeds of $1.0 million; 2015 - 24,639,128 common shares for net cash proceeds of $23.7 million).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="sA07F9F2DEEFA7E9F136282B9FBD6D8A1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div><a name="s0D2A11EF018C62273CAA82B9FC0859FF"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2017 Financing Activities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintained our Canadian ATM facility during the period ending March 31, 2017, however, no shares were sold under this facility during the period. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$10,500</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2016 Financing Activities</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the period between February 26 and March 31, 2016, we sold 545,500 common shares for gross proceeds of $274,805. We incurred share issue costs which included costs to establish our Canadian ATM facility of $375,349.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s656A0ADFBC400C3A53CD82B9FC298798"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents, short-term investments and working capital positions as follows: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, <br>2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br>2016<br>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,102,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,274,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We desire to maintain adequate cash and short-term investment reserves to support our planned activities which include our clinical trial program, product manufacturing, administrative costs, and our intellectual property expansion and protection.  To date, we have funded our operations mainly through the issue of additional capital via public and private offerings and through the exercise of warrants and stock options. In February 2016, we were able to raise funds through our Canadian ATM (our "Financing Arrangement"). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements.  In an effort to be able to evaluate all types of financing arrangements, we maintain a current short form base shelf prospectus (the &#8220;Base Shelf&#8221;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#8220;Securities&#8221;).  We renewed our Base Shelf on February 16, 2016 which allows to sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  Our Base Shelf expires on March 16, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maintaining our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. </font><font style="font-family:inherit;font-size:10pt;color:#ee2724;">&#32;</font><font style="font-family:inherit;font-size:10pt;">By utilizing our Base Shelf, we were able to enter into our Financing Arrangement. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Financing Arrangement provides us with access, subject to the respective terms and conditions, $4.6 million of which we have raised gross proceeds of approximately $1.5 million.  We expect to continue to access our Financing Arrangement to help support our current clinical trial, manufacturing, intellectual property and collaboration programs.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that the expected cash usage from our operations in 2017 will be approximately $12 million.  We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources.  Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources and access to additional cash resources through our Financing Arrangement to fund our presently planned operations into 2018.  Factors that will affect our anticipated cash usage in 2017, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical trial, the number of treatments each patient will receive, the timing of R&amp;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFE6E751A0C84CF22A9B482B9FC7DC7DA"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments and Other Instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable and accounts payable.  As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.  These financial instruments expose us to the following risks:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;&#160;We are exposed to credit risk on our cash and cash equivalents and short-term investments in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and short-term investments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties.&#160;&#160;As at December 31, 2016, 100% of our short-term investments were in guaranteed investment certificates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;&#160;We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.&#160;&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&#160;&#160;In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from financing activities.&#160;The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have  decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$17,516</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$34</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,247</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk  by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:420px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:197px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:70px;"></td><td style="width:4px;"></td><td style="width:64px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">U.S. dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,359,799</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,078</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,524</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285,884</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,214</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,073,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,524</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 8 of our interim financial statements.&#160;&#160;Accounts payable are all due within the current operating period.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCAAA58867243C791925582B9FCAECE97"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other MD&amp;A Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">121,836,722</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">May&#160;4, 2017</font><font style="font-family:inherit;font-size:10pt;">.  If all of our options, restricted share units and performance share units (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10,293,996</font><font style="font-family:inherit;font-size:10pt;">) were exercised or were to vest we would have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">132,130,718</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;Annual Information Form on Form 20-F is available on www.sedar.com.</font></div><div><a name="s8FE4C0F91028D16AF25882B9FCD07B6C"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal controls over financial reporting during the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;that materially affected or are reasonably likely to materially affect, internal controls over financial reporting.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>apc2.jpg
<TEXT>
begin 644 apc2.jpg
M_]C_X  02D9)1@ ! 0$ @ ![  #_X2@(17AI9@  34T *@    @ ! $2  ,
M   !  $   $R  (    4   (2H=I  0    !   (7NH<  <   @,    /@
M$'X<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 #(P,3<Z,#4Z
M,#0@,3$Z,3DZ,S$   *D(  "    (0  $%KJ'  '   'W@  "'P     '.H
M   (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         #$T,S%&,T(T-3,W0C0S
M0D)",C(W,C%#,$0W1$0S,$$S       & 0,  P    $ !@   1H !0    $
M !#, 1L !0    $  !#4 2@  P    $  @   @$ !     $  !#< @( !
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M KS_ +6X=/:EK<I<O+KN5[=M=-["L\=J+4.=[*V7*X;'XYV'\ZUZ9(44 %%
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MW0Z$Y.\):/U^XLVM[;WB[H'+<!N5(X.<=?H?RJQ23NKHN47%V844R0HH **
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M@L8XHU+.[W; *!U)/ETR"^OIRRI;V+,APP6[8X_\A^Q_*@";S=3_ .?2T_\
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M@"A;O>G5;E95/V4?ZLX&.BXP>IR2^<^@J_0 44 %1RPI,%#[OE.058J0?J*
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M#W% &G]BB_OS_P#@0_\ C7/ZQJ\&F:E]E$;R[8O-8C4'5E/8%??G'J<#C(-
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M!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!
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M$TNI:<NGS#2=+ B6<397S;X[L@#OD8]J8'>4444 %&*** "BBB@!,48-+10
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MD^G0W****U.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:R1(W<8#-O.0#^5=>K!U#*001D$="*4)7NGT'B*:BU*"T:0ZBBBM#G"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=  I68HI(4DE@1Q]W.!7AOAU+#4/%&B#43\<]2CBU""6*'6[3-FLH;Y'D/&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*N^-U&>PR1BB$E&Z;%7HN:C.$=UT]6=!1116QQ!1110 4444 %%%% !1110
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M<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)=02CP-E?8\U+]C\8_\ 00TG_OPW^-7[3R9B\*D[<\?O_P" =+17-?9?&/\
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MU5?<DCBNC1@P!'0\BM(S4MCFJ49T_C5AU%%%49A1110 4444 %%%% !1110
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MZ;:SQ.KZ@S(G?8P7.#^M:=*QI&I&3:3V'4444BPHHHH **** "BBB@ HHHH
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MTG_GI??^!4G^-=)11[./8/K=;^8YO_A =)_YZ7W_ (%2?XT?\(#I/_/2^_\
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M^@25M#K:***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5U'FWWR_ND1<9&>F>?H V!W5%%% !1110 4444 %%%% !1110 4444 %%%%
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M^%/J7_Q^@#JZ*Y3_ (5GHG_/_P"*_P#PI]2_^/T?\*ST3_G_ /%?_A3ZE_\
M'Z .KHKE/^%9Z)_S_P#BO_PI]2_^/T?\*ST3_G_\5_\ A3ZE_P#'Z .KI-U<
MI_PK70_^?_Q7_P"%/J7_ ,?JGIWPRMEDOCJ&J^))8VN";01^)=1!C@V+A6_?
M#)W;SDYX(Y[  [BBN4_X5GHG_/\ ^*__  I]2_\ C]'_  K/1/\ G_\ %?\
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M^%/J7_Q^@#JZ*Y3_ (5GHG_/_P"*_P#PI]2_^/T?\*ST3_G_ /%?_A3ZE_\
M'Z .KHKE/^%9Z)_S_P#BO_PI]2_^/T?\*ST3_G_\5_\ A3ZE_P#'Z .KI-U<
MI_PK71/^?_Q7_P"%/J7_ ,D52TSX96R"Z_M/5O$DQ:X=K?RO$FHC9!_ IQ,,
MD#J>?J: .YHKE/\ A6NA_P#/_P"*_P#PI]2_^/T?\*ST3_G_ /%?_A3ZE_\
M'Z .KHKE/^%9Z)_S_P#BO_PI]2_^/T?\*ST3_G_\5_\ A3ZE_P#'Z .KHKE/
M^%9Z)_S_ /BO_P *?4O_ (_1_P *TT3_ )__ !7_ .%/J7_Q^@#JLTN:Y/\
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MS_\ BO\ \*?4O_C]'_"L]$_Y_P#Q7_X4^I?_ !^@#JJ,_6N4_P"%:Z)_S_\
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M&!QV% '<45RG_"L]$_Y__%?_ (4^I?\ Q^C_ (5GHG_/_P"*_P#PI]2_^/T
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M9M9(Y)-OEPML$V]5RVYF(^4Y6J'B3QUKUGK>MQ_\) VG:I9WD4.D^'1;1/\
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MFEVFEHH **** "BBB@ HHHH ;M-+MI:* $VTM%% !1110 4444 -VTNVEHH
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M/%^E:YXD7P58KI,[74<GA[3W@N+N0@KB9C@8.<G&>:]HQ2T47TL%M;A1110
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M72;$8QNQ'"CMC)^9O:L*\^('C)?A4VJV][<F1M?N+*\U**U$TMA9K,R^8D8
MW%0 !D'K4WT3[H=NA[Z\JQJ68\*,GZ5F>&O$^F>+=(BU;29GFM)F=4=D*$E6
M*G@X/4&O+?@_XOFUR[O[9/B-;^++0VSN(+NT^RZA;R*0#F,#_5X[GG-<A\(?
M&.H>)+71OA]HFIR:']EDNKR_OF0>;<*MPQ\BWW@@G# LV#@>]5UL)[7/I:BF
MJ,*!G.!^=.H&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHPD336Z/(J@=!N^;';=[T+7^O.P'H=%%% !1110 4444 %%%% !129'K1NH
M3'J:Y[3?!&GV?AW4/#]PSWEEJ$MW),L@ R)Y'=EX[#>17149% '(Z-X+UC3K
MJV-YXQU2_LK2-HX;8QQQ$Y&U3(ZC,A ]>_/6HK7X>WCZGIUUK7B:\U>#2I&F
MLH9H(T9'*,@9Y% 9R%9ASU/)Z5V>:,T!Y&#X*\+MX-\.V^AC49;^"TREN\L:
MJR1?PH=O7'KU-4-+_P"2I^)/^P-I7_HZ_KK-PKE-+_Y*IXD_[ VE?^CK^@#K
M:*** .8USPA>WVL?VOI'B"ZT>[D@%M/MC6:.5 25^1^%8%C\P[&IM+\%Z?H_
MA-O#=FTB0212H\S'=)(\F2\C'NQ9B3[FM_-+FE;2P7UN9OAS1(_#?A_3-%BE
M>:+3[6*U21_O.$4*"??BM.DR*6F]=02L%%%% !1110!QFL?#ZZO[S47L/$M_
MIMGJN#>VJ(L@<[0A,;-S%E0!\O?FDO/AK%!<V-WX9U.;P]<6EDNG;H84E62V
M7[B%7XRIY#=>3ZUV6?K2YI 9/A?PU:>$]#M](LFD>.'<S2RG+RNS%G=CW+,2
M3]:UZ3-%,!:*** "BBB@#@3\-M6@\3ZIXAT_Q=-;W6HE03)I\,QAC486-&89
M"]\=S6AJ7@G4KB^&HZ?XHO-/OI;9+:[D6!)$N N<,$;Y4;);E?7VKK<@T@:E
MV0=;F9X9\.67A31;;2-.5A! #\SG<SL269F/<EB2?K6K1FBF 4444 %%%% &
M'XG\*P>)FTIIKF2'^S;^*_38 =[)G"G/;FL_6O TMWK<FMZ-K5QHM_<PK;W;
MQQ)*MQ&OW<J_ 89.&'.#759HS2L!G^'= L_#.CVVE:>A6WMP0,G)8DDLQ/J2
M23[FM*BBF 4444 %%%% &'XD\*P^)9M)EFN)(3IE]'?($ _>,N<*<]N:HZSX
M+O;S5Y]3TGQ#>:3)=QK%=1K&LR2JO *J_"-@GD5U.Z@,#2 S_#^@V7AG1[;2
M=.C\NUMEVH"<DY)))/<DDFM&BBF 4444 %%%% &%XC\*P>([K1[B:XEA.E7J
MWJ! /WC!6&TY[?-6%JGPYU&[\83^*++Q1+:7,D*V\4<EC%.+=!U$9;E<GDXZ
MUW.X>M&:0%73+6ZM;&&&]O3?7"KB2X,8C\P^NT<#\*MT44P"BBB@ HHHH Y_
MQ1X1C\126-[#=R:?JFG.SVE[$H8Q;AA@5/#*1U![@'M3O"_A5/#OVRXENWO]
M2U"437EY(BH9F VK\J\*    *W<T;A0 M%%% !1110 4444 8/B;PO+KDEE=
MV>JW.EZA8LYAN(@'7# !E:,_*P( Z].U+X7\*Q>&UNYFN7O-0U"7S[V\D4*T
M\FT*#M'"@   #I6YN%&X4(!:*** "BBB@ HHHH Y#QQX"F\97NDW*:U)8C3)
M6G2 VT<\4DA& [*_!*\X],ULZ!INJZ=;R1ZKK1U:1GRDAMDAV+_=PO!^M:N:
M,TNE@%HHHI@%%%% !1110!SWBKPBOB.2PO;:_FTS5--D:2TO8D#F/<-KJ5;A
ME8=0?0'M3O"?A)/#$5]))>S:AJ&HW!NKR\F4*TTF HPHX55554 =A6]N%&X4
M(!:*** "BBB@ HHHH Y[Q5X1'B*;3[ZVOY=,U739&>TO8D5R@==KHRMPRL.H
M/H#VIWA/PFGAB&]9[V:_O]1N&NKV\F 5II" H^4<*H554 < "M[=06 H0"T4
M44 %%%% !1110 4444 <%<27GC;QGK&AKJM]INE:$ENLHL)##-<7,J%^9!R%
M52G ZECGH*M)<7GPZT?5[S6M6GU;3('0Z>L@+WGSX7R6<G]X2Y 4GGG!-)J6
MB:[H?BF\\0^&[6RU!=4BBBOK"YG,!W1A@DJ2!6YP=I4KR I!&.<S4/!'B?Q;
MI.LRZ[J,-M?7<EO+I^GQ.TMK8F"02)N/!=F8#>V!QP.F:70?4L7/Q.N=%AU&
M+Q%X>?3;^VTN;5X+>.[69+F*(#>H<*,."5R,$88')YQB^)_BOKEIX?U$Q^&W
MTV_GT6XU33));I7W1Q@;BX"_(ZAU;9R#TS4_B#P=XL\<+J%[JUKIVEW":'>Z
M996D-T9UDFN%4-(\FQ=JC8H VD]23T%6O&GP_P!6\11645M);+Y7A_4-,=G<
M\33QQ*A''(RC9Z?C2=[/^N__  !QM=?UV_X)9T?QYJ]QJ>G^'Y/#X:].G6^H
M7L[7P\N&)W="=VSYV^3=MP,Y/(QREO\ %-YA::G/H4T'AN_NTL[35#<*S.SO
ML21HL96-FX#;B>5) SQ+X9\,ZROB&35]8M[2U6;0[;37A@N#*5DCDF+8.U<J
M5=2#CU].<6T\!^*&T'2O ]Q%IT6A:7=V\@U*.=C-<6\$@D2/R=ORN=JJ6W$<
M$@<@"GOK_6O^1"V_KM_F;_@#6YYM!UJ^U.ZFF6TU;4DWL"[)%'<2!5  R0%&
M  ,U%X3UJRUSXD^)KJQ>5XETG2XR9(7B.[S;X]' /0CFM7P)X?O/#VG:A;WI
MBWW&J7MXGEL2/+EG=USP.<-R*KZ6/^+J>)?^P-I7_HZ_I+9#>[]6==1113 X
M7QCI.JZAJ\UYJ'B*XT+PKI]BTI>RNC!+)/D[FD;'"*H! S@D\]*XSP]XB\1>
M+$\$:'K&JWVG0:G:7MU)=PM]GN;\0R 0 ,!E2T9$A P2!Z<5T?CKP[XI\0>*
M;5CI%GJ_AJTC65+%]2-LL]SG.Z9?+;>JX&U<XSDG/%7O%&EZYXBTG3$O/!WA
M_4E5W:YTZ[O#^Z('R/%-Y>/J"G?KQRHZ*X/</A5XFFUNWU_3;B__ +1.A:K+
MI\=V6!:6-0K+O(ZL-Q4GOMR>2:[NN4^'OA*3PKIEV;E+6*\U&Y-W/#:KB&#Y
M51(D]0J(HSQDY.!G%=73 6BBB@ HHHH \J^(%IK5E#XD\2:QXKO-$L;.)4T:
M'3[@J"VT'=*F/WCL_P H4Y&/K2>,I;FW\ VOBK5KS7K/7);&WB&G6-_);I)>
M2 !4V*>N]L'O@>U2ZMX?\8WOCF;6[W0-/UJQLV4:1;R:J88X./FE:/RF#2DG
M@DG Z8/-;_B;PYJOB?4/"4\L,$%MI]Z+^_A\\L5=8FV!3M&_$A!YQTJ4M$'6
MYJ^"]%U+0/#-AI^K:I/JM_%&/M%W.VYI)#R?P'0>P%;M)BEJV[B2L%%%%(84
M444 >:_$S6O%FEZ_X:2PFMK/1)M6M(+B16+7%R7?!3&,*F.O))Z<"H]8N+[Q
M)\0M8T.XUZ^T>QTK38KNW2RG\AYG<OND8CEE7:!MZ<\UT7CWPU?>)%T(6)B'
MV#5[:]F\QMO[N-LMC@Y-9GCOPWJFM:M#+%X3\.:[!%"1!-?3M%-:RD\G[K!T
MZ' QR/RGI]_Y#Z_=^9?^$_BN?QGX%T[6+J2.:XD\R.26,864H[+O _V@ ?QK
ML*PO!7AE?"/ANTT@2K,\6]Y9538KR.Y=R!V&6.!Z8K=JWN2@HHHI#"BBB@#S
M7XD:UXLTSQ-X9CL9K:ST.?5;:"=E8FXNBQ.4QC"H._))]AU7XUZSXKT7PW]I
M\/2VUE:QM&UW=LQ,P!D4>7&N, G/+$].W>MWQWX:OO$3Z ;(Q :?JT%[-YC8
M_=H3G'!R>:=\3/#5]XL\'7FCZ<81<SM&5\UMJC:ZL><'L*4>GK_D5I=>AU"'
MY0?:G4U1M4"G&F0@HHHH&%%%% &=K>DQZU8FTDO+^S7<&\VRN&@D&.VY><5P
M7PFM[W4M5UO7EUO6+K0S,UEIUM?7;S[Q&<//EO[S< >@KO?$%O>76AW]OIY0
M7DMO(D!<X4.5(!)],U3\#Z WA?PCI.C.%\RSMDCD*G(+X^8Y]VR:%NP>QNT4
M44 %%%% !1110!PGQ9\72^%='T](9I+=M3OX[%IXT+/$C9R4 _C.,#W.:J_#
MN\F37]4T]M2UP0B".5-+UX;[N$G(,BR;FW1MZ9X(-;?C[PI<>)K&QDL98DO]
M,O8[^V$PS'(Z9^1O0$$C/:JGA[P]JUWXPN/%NNVEMIUR;);"&SM[DS@('+EV
M?:N22< 8Z"E'S_K3_,)>1VM%%%, HHHH **** ,/Q=XA'AW23/%'Y][.PM[*
MW'6>=N%7Z=R>P!-<]\%M2UK5?!?G>(+TWNI)>W44TG;*RL,#V&,"MSQ+X)T[
MQ3=V5W>7&I6]Q8[_ ")+*\D@9=P /W",]!65\*O!-WX&T*[LKZZGGFFO9K@>
M9=/,%1G)7&[H<8SZGGFDNH/H=M1113 **** "BBB@#EO&6D:]KEQI=CIFIOI
MFF&5WU*XMY3'<E !L2,XXW'J1R ..M8_PEU:[U&+7X#J-SJVDV6I/;Z=J%PV
M]YXP 6&_^,*Y90W?%3?%#1?%'B&"PTW1K>*;2G=CJ<?V\VDLZ8XC#A&PI.=V
M,$CC/6MWPBFH6^FBSO= LM#BML1V]O:7?GIL _W%QSVQ1'J$NAO4444 %%%%
M !1110!S_C6XU^UT"=_#:V?VX@CSKLG9 NTDR;0/F(P,+P,GD\8-3X6:A>:O
M\.?#FH:A</<W=QI\,DTSGYG<H"2:Z'4K=[K3[F"/&^2)D7/3)&!6/\/=#NO#
M'@?0]$OS&;JPLHK>7RVW+N50#@]Q1'[7R_4'T.BHHHH **** "BBB@#@_'.H
M7E]XL\-^$+2_N=/@U);FZNY[23RYS'"$PBMU7<SC)'.%QWI?A[J=Y%KWBKPK
M>7T]^NB74)MKBY?=,89HA(JNW\14EAD\D 9JUXR\.ZI<ZWH?B70X[>XU#2#-
M&;6XE,27$,R@.-X!VL"J$'!'!'?(?X'\.:GIU[KNNZVMM%J6MW2S/!;N9$MX
MHXUCC3>0"QPN2< 98X%$?Z_KT!G74444 %%%% !1110!P7C?4+S4/&'ASPA:
MZA<Z?!J$=S>7<]I)Y<[1PA-L:OU7+2 DCG"D=Z?\/-3O4UOQ5X7O;Z>_&A7D
M0M[BX;=,89H5E57;^(J2PR>2 ,\\U9\8^'=5GU[0_$^A1V]Q?Z3YT+6EQ*8D
MN()@H8;P#M(*(P.".".^0_P-X<U+3+O7-;UI;>/4];NUGD@MW+I;QI&L<<>\
M@;CM7).!RQP*(]?Z_K0'T.NHHHH **** "BBB@ HHHH 3;1BEHH 0@T;:6B@
M!-M&TTM% "8KAK^\U/P[\0M5U./PSK&K6=]I=C!'+IXA(62*6Z+JPDD0CB9.
M@-=U28H Y+_A/=0_Z$#Q=_WQ:?\ R11_PGNH?]"!XN_[XM/_ )(KKJ* .0_X
M3S4/^A!\7?\ ?%I_\D5 GQ*FDO);)/!'BMKJ!$EEA$=KE$<L$;_7XP2C]"?N
MG..,]H2*RM*U3P]JVHWTFDW^F7E]%MM[PVLR221[2^U)-I)&"9, ^K>] &/_
M ,)YJ'_0@>+O^^+3_P"2*7_A/=0_Z$#Q=_WQ:?\ R17744 <C_PGNH?]"!XN
M_P"^+3_Y(H_X3W4/^A \7?\ ?%I_\D5UU% '(_\ ">ZA_P!"!XN_[XM/_DBC
M_A/=0_Z$#Q=_WQ:?_)%==10!R'_">:A_T('B[_OBT_\ DBH+?XDS7<EQ';^"
M/%<KVTGDS*L=J#')M#;3F?D[64\<<]>M=KFJ5F=-2ZO8;-K47/F++=I$1OWE
M0 S@<Y*J ">RCTH Y_\ X3W4/^A \7?]\6G_ ,D4?\)[J'_0@>+O^^+3_P"2
M*ZZB@#D?^$]U#_H0/%W_ 'Q:?_)%'_">ZA_T('B[_OBT_P#DBNNHH Y'_A/=
M0_Z$#Q=_WQ:?_)%'_">ZA_T('B[_ +XM/_DBNNHH Y#_ (3S4/\ H0?%W_?%
MI_\ )%06_P 2IKQIUMO!'BN5K>4P3!8[4>7)@-M.9_1E/&1S]:[&::*WB:6:
M18XT!9G8X"CN2>U9OA_4= U:&XO/#][IM[#+,7FFL9DE5Y=H!+,A(W8"]>P%
M &/_ ,)[J'_0@^+O^^+3_P"2*/\ A/=0_P"A \7?]\6G_P D5U]% '(_\)[J
M'_0@>+O^^+3_ .2*/^$]U#_H0/%W_?%I_P#)%==10!R/_">ZA_T('B[_ +XM
M/_DBC_A/=0_Z$#Q=_P!\6G_R17744 <A_P )YJ'_ $(/B[_OBT_^2*@M?B7-
M>M.MMX(\5S-;RF"8+':_NY  2IS/UP0>,CGK77W%Y;VFPW$\4(D=8T\Q@NYB
M<!1GJ2> *S+_ %KPUX4DQJ&I:3I#WLIDQ<3QP&>0X!;YB-QX _*@#*_X3W4/
M^A \7?\ ?%I_\D4O_">ZA_T('B[_ +XM/_DBNL5U=0RD%6&00>"*=0!R/_">
MZA_T('B[_OBT_P#DBC_A/=0_Z$#Q=_WQ:?\ R17744 <C_PGNH?]"!XN_P"^
M+3_Y(H_X3W4/^A \7?\ ?%I_\D5UU% '(?\ ">:A_P!"!XN_[XM/_DBH+7XE
M37OG"U\$>*YO(E:"7;':CRY!U4YGY(R.F1[UU]Q>6]KL^T3Q0^8XC3S'"[V/
M11GJ3Z5G7VK>'?":>9J.H:7HR7D[-NN9XX!-*1R?F(W-Q]:0&3_PGNH?]"!X
MN_[XM/\ Y(H_X3W4/^A \7?]\6G_ ,D5U:2)(BNC!E89#*<@CVI],#D?^$]U
M#_H0/%W_ 'Q:?_)%'_">ZA_T('B[_OBT_P#DBNNHH Y'_A/=0_Z$#Q=_WQ:?
M_)%'_">ZA_T('B[_ +XM/_DBNNHH X__ (3S4/\ H0?%W_?%I_\ )%0VOQ*F
MO?-^R^"/%<WDRM!)MCM1LD7[R\S]O;CWKH;SQ1H.GZG%I5YK>F6VH38\JUFN
MD2:3/3:A.3^ IEYJGA[PNR)>W^F:2;^=F03S)";B5L9QDC<Q]N:0&3_PGNH?
M]"!XN_[XM/\ Y(H_X3W4/^A \7?]\6G_ ,D5UH(/0TM,#D?^$]U#_H0/%W_?
M%I_\D4?\)[J'_0@>+O\ OBT_^2*ZZB@#D?\ A/=0_P"A \7?]\6G_P D4?\
M">ZA_P!"!XN_[XM/_DBNNHH Y#_A/=0_Z$#Q=_WQ:?\ R14%E\2YM2M8[RR\
M$^*[BVE7='*D=J P]>9P?S%=#'XIT&75FT=-;TQ]37[UDMTAG7ZIG=^E3@Z;
MH-E#%NM;"T0B*-2RQHI)P%&>,DG %(#G_P#A/=0_Z$#Q=_WQ:?\ R11_PGNH
M?]"!XN_[XM/_ )(KKJ*8'(_\)[J'_0@>+O\ OBT_^2*/^$]U#_H0/%W_ 'Q:
M?_)%==10!R/_  GNH?\ 0@>+O^^+3_Y(H_X3W4/^A \7?]\6G_R17744 <A_
MPGFH?]"#XN_[XM/_ )(JO8_$J;4K2*\LO!'BNXMIU#Q2I':X=3T/,^<?4"NB
MC\4:#-JS:/%K>F2:FF=UDMTAG7')R@.[]*8NK^'-"NK3P^-2TJPN60"VT\SQ
MQR,O.-D><D<'H.U &3_PGNH?]"!XN_[XM/\ Y(H_X3W4/^A \7?]\6G_ ,D5
MUM+0!R/_  GNH?\ 0@>+O^^+3_Y(H_X3W4/^A \7?]\6G_R17744 <C_ ,)[
MJ'_0@>+O^^+3_P"2*/\ A/=0_P"A \7?]\6G_P D5UU% '(?\)YJ'_0@>+O^
M^+3_ .2*@L?B5-J5G#>V7@CQ7<6LZ"2&9([4*ZD9!&9P1D>HKI(O$6BW&K2:
M/%J^GR:G$N][);A#.B\<F/.X#D<X[U637/#.B7=MX=75-(L;H*L=OIWVB-)-
MN/E"QYST'&!0!F?\)[J'_0@>+O\ OBT_^2*/^$]U#_H0/%W_ 'Q:?_)%=;FB
M@#DO^$]U#_H0/%W_ 'Q:?_)%'_">ZA_T('B[_OBT_P#DBNNHH Y'_A/=0_Z$
M#Q=_WQ:?_)%'_">ZA_T('B[_ +XM/_DBNNHH X__ (3S4?\ H0?%W_?%I_\
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M[.3^7TH*;6@KZBT444AABC%%% !1110 4444 %%%% "<TM%% !1110 4444
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4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ittgroup.jpg
<TEXT>
begin 644 ittgroup.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (W R0# 2(  A$! Q$!_\0
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MNW]:7#I?^NQV=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M')9G7@ECVQP!7<444NE@ZW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHJ.XB::WDB2:2%G4J)8\;DSW&01GZ@T, CN()998HYHWDA(61%8
M$H2,@$=N"#SZU!J.JZ=I%N+C4[^ULH2VT27,RQJ3Z98@9KEO VF0:/JWB>SM
MWF=5OD9I)Y6D=V,*%F9CR222:M%5G^)[+-\P@TI3"K'(!>1@Y ]]JC\*GFO:
MW7_*XF[+7^M;'4(ZR(KHP9&&593D$5@Q_P#)0[C_ +!47_HV2J?@8R1^';V&
MW"NMO>W,5LCOA=JN0JY .!VZ''I2Z9)J$GCZZ.HVMK;R?V7%M6WN&F!'FOU+
M(F/RIIII-=1^1U=%%%, HHKF/%$^K^5+%!:1?80%WRLP+$Y'0;ACG Z&IG+E
M5S2E3=2:BNOI^K7W;G3T5ST$OBN5<_9],A XQ*6)(_X"34S?\)3D;?['QWSY
MM4M;>9E4?(Y+?EMMUOV[VZFW17/65]KNH0M+;2:3(BN8R=LH^8=1S3GU+5[&
M_L8;^.Q>*ZE\H>1OW XZ\U#G;=,Z(4.=7A)/T9OT4459@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!G6VCPV=SJ=Q!/,DVH.))
M&RIV,$" J",= #SGFJM_X;6]EM;E=4OK74+>(Q?;H!$)9$/4,&C*'GG[HQVQ
M6W12LK6 IZ7IEKH^GQ65FA6&/U.2Q/4D]R3R367'_P E#N/^P5%_Z-DKH*Y^
M/_DH=Q_V"HO_ $;)3 Z"BBB@ J*XMXKJ!H9TW1MC(R1[]JEHH:ON--IW0=!B
MBBB@1DS:/-#:B#1[S^S@9&D<^4)MQ/7[QXYJ+7-(OM0M[)K2\CCN[60.)'3A
MCC!..<>N,5MT53DWN9QI1BWRW5^S:^ZS5OE8P]*U+4&U>?2M16W:6&%91+!D
M @G'(/?Z8K<KG-4T;5WUE]0TF^AMVDB$;^8N3P?<&EGMO%DL*)'?:?"R]71"
M2WUW*1^0%2FM.GW_ '[&CC-<S7O=5\*WZ*[Z=W:^YT5%<Y<0>*Y($5+_ $Z
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M<\.XWU4M/FG?UV1T5%%%49!1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGX_^2AW'_8*B_P#1LE,25CH****!A1110 4444 %%%% !1110 4444 %%%%
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M5"+T?KH=/16-_P )5HO_ #^_^0G_ ,*/^$JT7_G]_P#(3_X57M(=T8_5:_\
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M4 %%%% !1110!S^I^&[.XN(YXK3=))<!ISYA&5YSW^G2MFSLK>PMQ;VT?EQ
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M<_'_ ,E#N/\ L%1?^C9* .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5''_ ,E#N/\ L%1?^C9*UFTY-H1T%%%%2 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *XCQ=X4T;^P)(#X5N-9M)M0:^N[:VNV20
M.58M*N77<<\; 1][@<5V]<QXWU?4M)TRQ_LR6*WDO+Z.SDNI8/-6W60,!)MW
M*.&V_>..>AX!/)?UJ-'#^'/#WPADUFV%MIS:7KEO)%*EEJ4]Q;W$<A^9!LD?
M#G@?=W#IZBO7ZY*S\!PO=0WVOZQJ>NWL3Q3)]IF\NWCE08#QP1[47\0Q]\Y)
MZVF]K$]0HHHI#"BBH[BXAM+>2XN)4BAB4N\CMA5 ZDGTH;MJP)**S-+\0:;K
M,DD=G++YL8#-'/;R0/M/1@LBJ2IYPP&..M+JFO:?HS1I>22F64$I%;V\D\C
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M31$MBB0WKWJ+E1,\@<G'8L.N/SH:5M"HSDVDU;3O^!;HHHJ30**** "BBB@
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M^+?$-EI>M:]X-,.FWB7ES:Z//(]UNB/"LK_=&[ /0BO5:O[*_KL)VN%%%%2
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MJM/NON_X)CS4/Y7_ .!+_P"1,;_A*M%_Y_?_ "$_^%'_  E6B_\ /[_Y"?\
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M*VZ**E1LV^YI.HY1C'M_G<****HS"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Y2_OTTCQP]W<VNHO;RZ:D:R6NGSW(W"1
MR0?*1L'!'6NKHH Y_P#X3+2_^?77/_!#>_\ QFC_ (3+2_\ GUUS_P $-[_\
M9KH** .?_P"$RTO_ )]=<_\ !#>__&:9_P )OHWG>3Y>L>=MW^5_8MYOV]-V
MWRLXSQGI71UE6UWH=[KT[6E]9SZI!%Y,T<5R&DC3=G#(#QSZB@"I_P )EI?_
M #ZZY_X(;W_XS1_PF6E_\^NN?^"&]_\ C-=!10!S_P#PF6E_\^NN?^"&]_\
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MR*C/M#*"=N"[]@>?:@"M_P )EI?_ #ZZY_X(;W_XS1_PF6E_\^NN?^"&]_\
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M(ZXW$9J.>?1M/,FOW-W:VZ2PQQ->2W 6,Q@L4&2=O5VY[Y^E %+_ (3+2_\
MGUUS_P $-[_\9H_X3+2_^?77/_!#>_\ QFMJUN[:^M8[FTN(KBWD&Z.6%PZ,
M/4$<$5-0!S__  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",UT%% '/_
M /"9:7_SZZY_X(;W_P",T?\ "9:7_P ^NN?^"&]_^,UT%% '/_\ "9:7_P ^
MNN?^"&]_^,TS_A-]&\[R?+UCS@N\Q?V+>;PO3=M\K.,\9Z5KZCJVFZ/ )]3U
M"TLH6;:)+F98U)],L0,U!=SZ-ISG7;R[M;97B6'[7-<!(RF2RC).WJ2: *7_
M  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",UL65]::C:I=6-U!=6[_=
ME@D#HWT(X-6* .?_ .$RTO\ Y]=<_P#!#>__ !FC_A,M+_Y]=<_\$-[_ /&:
MZ"B@#G_^$RTO_GUUS_P0WO\ \9H_X3+2_P#GUUS_ ,$-[_\ &:Z"B@#G_P#A
M,M+_ .?77/\ P0WO_P 9IG_";Z-YWD^7K'G%=XB_L6\W[>F[;Y6<9XSTK8U#
M5-/TBW^T:E?VME!G;YMS,L:Y],L0*BE;2HF_MZ:>!$2W*_:WFQ&(B0V<YVXR
M <T7 S_^$RTO_GUUS_P0WO\ \9H_X3+2_P#GUUS_ ,$-[_\ &:U[#4;'5+47
M6G7EO>6Y.!+;RK(A/U4D59H Y_\ X3+2_P#GUUS_ ,$-[_\ &:/^$RTO_GUU
MS_P0WO\ \9KH** .?_X3+2_^?77/_!#>_P#QFC_A,M+_ .?77/\ P0WO_P 9
MKH** .?_ .$RTO\ Y]=<_P#!#>__ !FF'QOHPF6$QZP)F4NL1T6\WE1@%@OE
M9(!(!/09'J*Z,D 9)P!68TVC.%\0&[M3'!!)&+WSQY2QE@7RV=N,QC)/3;]:
M *7_  F6E_\ /KKG_@AO?_C-'_"9:7_SZZY_X(;W_P",UL65_9ZE:)=V%W!=
M6TF=DT$@=&P<'##@\U8H Y__ (3+2_\ GUUS_P $-[_\9K0TS6;75O-^S17T
M?E8W?:K">VSG/3S47=T[9QQGJ*T** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH S?$$LL'AO4Y821*EK(RD'!!VGFN/D@AL]'\#RVN%D%Q$@93
M@LKH2X]\]Z] DC2:)XI%#QNI5E(R"#U%8&G^$+.PNK>4WM[=0VF39VUPR&.V
MS_=PH8^@W%L=JFSO]WX/]1-?K^)T-%%%4,**** "BBB@"AK6K6VA:-=:G>,%
M@MXR[<XS[5YIX*U33[CXG7%U)K-A=7^HZ;OD$%XDJJ_F B%,''RKUQU.37K5
M9JZ);)XC?7 \OVI[;[*4R-FW=NSC&<Y'K1'25W_6C*37*U_70TJ***"0HHHH
M **** ,GQ1+;P>%-6DNYY8+=;24R2PC+HNTY*^_I7&Z1;WMEKG@V/5K2*R6&
MSDM+,VS;S,?*!VS#CROE0ML4R#</O<#=Z#>V=OJ%C/97<0EMYXVCEC;HRD8(
M_*L;3O"<5E>VES<:KJ6HFQ0I9QWCQE8,C:2-B*6;;QN<L<$\\G*5U*_]=?\
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MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52O\
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M: $@/*W4J"6VIW.>G)K(OM OM)TG1_#]IIM]JNDQL\^HR0O KW,F[?L822(
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ME1112*"BBB@ HHHH 0D*"2< <DUS,'CBQN)K=A8WZZ=<W'V:#4V1/L\DF=H
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MWE61"1VRI(JU3=^H+R"BBBD 4444 9.H>%_#^K77VK4M"TR\N-H7S;FTCD?
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MG;,0HFN)EC0D]!N8@4M +E%4].U73M8MS<:9J%K>PAMIDMIED4'TRI(S5RF
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MBBB@ HHHH **** "BBB@#D--'V[XF:X]X@=]/M[>.R#K_JT=2SLONS9!(_N
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MGD=$?S%5B=F01E03R"<G.:ZJL_2-'@T:WECBDFGEGE,]Q<3L#)-(0 6;  Z
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M_P"&[2_L+*V,UQ!+8E3:W4)7S8B!C(R"IR.H((/I4QNI7Z:?K_P DKQLO/\
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MOPQ\+7=HH:ZCNK:2.08W%W;YSGU.3FO4'19$9'4,K## ]"*YNU\$V5K<6O\
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MD#_2?X=HSR?O#IWZNL:U\4:;>>*KOP[;N\E[:0"><J!L0$@!2<YW<YQCI1Y
M0?8_&'_0=T/_ ,$TW_R51]C\8?\ 0=T/_P $TW_R57044 <_]C\8?]!W0_\
MP33?_)5'V/QA_P!!W0__  33?_)5=!10!S_V/QA_T'=#_P#!--_\E4?8_&'_
M $'=#_\ !--_\E5T%% '/_8_&'_0=T/_ ,$TW_R552,^-)-6N;(ZAHZ10PQ2
MK='1YMDI<N"@'VGJNP$\G[XX'?IKJYALK2:ZN)!'!"ADD=NBJ!DG\JP]*\76
MNIWEK;/87]E]MB,UE)=*@6Z0 $E=KL5."#M<*<'IP<'6P=+B_8_&'_0=T/\
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M0<%B795 SQUR>PJI+XUTW[!I]Q9PW=_+?N8[>VMD7S"R_>!W,JKM[Y(H ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>oncylogoa04.jpg
<TEXT>
begin 644 oncylogoa04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[2Q64&AO=&]S:&]P(#,N,  X0DE-!"4
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M=#PO<W1R:6YG/@H\+V1I8W0^"CPO<&QI<W0^"CA"24T#Z0      >  #
M2 !(      +> D#_[O_N P8"4@-G!2@#_  "    2 !(      +8 B@  0
M &0    !  ,# P    %__P !  $               !H"  9 9       "
M                                 #A"24T#[0      $ $L     0 !
M 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M!    !XX0DE-!!D       0    >.$))30/S       )           ! #A"
M24T$"@       0  .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-!         (  #A"24T$ @       @
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      T4    &              #A   #P     @ 3P!. $, ( !,
M &\ 9P!O     0                         !              /
MX0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MX0    !29VAT;&]N9P   \     &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   .$     4F=H=&QO;F<
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M '0 ;P!S &@ ;P!P    $@!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<  @ $, 4P    $ .$))300&       '  @    ! 0#_X0E@17AI9@  24DJ
M  @    ' !(! P !     0"+>1H!!0 !    8@   !L!!0 !    :@   "@!
M P !     @"]#S$! @ =    <@   #(! @ 4    D    &F'!  !    I
M ,X    L 0   0   "P!   !    061O8F4@4&AO=&]S:&]P($-3($UA8VEN
M=&]S: " ,C P.#HP-3HR,B Q-3HR.3HS.  #  &@ P !     0#__P*@!  !
M    P ,   .@!  !    X0         &  ,! P !    !@#F_QH!!0 !
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M^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_HG>S^VMKZL_\
M-3T[/^;_ *.^?T\3Z_\ Z$?:/UO_ +=7SBDHX[CY?I_W*?M?JI)?*J2E0_52
M2^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224_522^54
MDE/_V?_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:
M( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M  #VU@ !     -,M2% @(
M                        $6-P<G0   %0    ,V1E<V,   &$    ;'=T
M<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M%&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
M    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@
M  0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E
M>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP
M86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M$G-21T(@245#-C$Y-C8M,BXQ
M                              !865H@        \U$  0    $6S%A9
M6B                      6%E:(        &^B   X]0   Y!865H@
M    8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6
M245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W
M=W<N:65C+F-H
M             &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M              !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X
M   !6%E:(       3 E6 %    !7'^=M96%S          $
M           "CP    )S:6<@     $-25"!C=7)V        !      %  H
M#P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\
M ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L
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MMGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#
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M!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Z*-/DCYDMW"BBBMA!1110 4444 %%%% !1110 4444 %%%% !2$ C!Z4M%
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M117>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/C^V%SX*U
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M # %90I2J+FFP;ML>0V_PFU>0 W%]9Q9[+N<C]!4DOPCU%5_<ZG:NWHZLO\
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M=17)?$>[2V\&72,1NG9(U![G.?Y U%3X&-;GAE>L_"*8G3=1A.<+*K#\1_\
M6KR:O8/A-:-%H-W<L,":?"GU"C_$FN##?Q$7+8] HHHKTC,RO$__ "*VJ_\
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MJ[885VCU/J3[D\U)9V5MI]LEM:0)#"GW408 J>MJ5%4UYB;N%%%%;",KQ/\
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M7@?0[OP_X>^R7NP3-*TA"-D ' Z_A7'AZ<HSNT7)Z'2T445W$!1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.0:6J]C90:=916=JA2"(812Q.!]35BM$(**** "BBB@ HHHH **** "BBB@
MK'USPSI?B&'9?6X,@&$F3AU^A_H>*V**32:LP/%]=^&6K:<6ETXB_M^N%&)!
M_P ![_A^5<7-#+;RF*:-XY%ZJZD$?A7TY5'4-'T[58]E_90W ]77)'T/45RS
MPJ?PE*1\W*S(P9201T(-;-GXMU^P $&K7(4=%=]X'X-FO2M0^%6C7!+6<]Q:
M,>BYWJ/SY_6N=NOA+JD9_P!%O[68?[89#_(UC[&K'8=T9T/Q.\21@!IK>3W>
M$?TQ4_\ PM3Q!_SSLO\ OT?\:JR_#7Q/&?ELXI?]R=/ZD5%_PKKQ5_T#!_X$
M1?\ Q5%Z_F&A9E^)WB24$++;Q^Z0C^N:Q[SQ;K]^"MQJUR5/54?8#^"XK4B^
M&OB>0C=9Q1?[\Z?T)K3M?A+JLA'VJ^M81_L;G/\ (4N6M+N&AY^S,[$L22>I
M)IT44D\BQQ1M([<!5&2?PKV#3_A3H]N0UY<7%T1_"#L7].?UKKM.T73=)CV6
M%E# .Y1?F/U/4U<<+)_%H',>2:%\,]6U(K+?XL+<\G>,R$>R]OQKU'0O"^E>
M'HMME;CS2,/._+M^/8>PK9HKJIT8PV);N%%%%:B"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
